IceCure Medical Ltd. has highlighted the recent U.S. FDA marketing authorization of its ProSense® system for the local treatment of early-stage low-risk breast cancer in women aged 70 and above, when used with adjuvant endocrine therapy. ProSense® is described as a minimally invasive cryoablation device utilizing advanced liquid nitrogen technology to freeze and destroy benign or cancerous tumors with minimal pain. The device is approved for use in multiple countries and has received recognition for its clinical impact. IceCure Medical notes the assignment of a CPT Category III code for breast cancer cryoablation, supporting reimbursement for eligible procedures. The company is also conducting a post-marketing study to collect additional data on the device's use. You can access the full presentation through the link below.